Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 1.00 |
| ▸ | TDO2 | P48775 | 5/20 | 0.62 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7815259 | 0.78 | IDO1 (0.63) | IDO1TDO2ALDH1A1RAB9ATGFBR1 | |
| SCHEMBL7808047 | 0.78 | IDO1 (0.79) | IDO1TDO2KDM4EALDH1A1KMT2A | |
| SCHEMBL7816954 | 0.77 | IDO1 (1.00) | IDO1TDO2KDM4EALDH1A1NPC1 | |
| SCHEMBL7805902 | 0.76 | IDO1 (0.63) | IDO1TDO2KDM4EALDH1A1NPC1 | |
| SCHEMBL7812685 | 0.74 | IDO1 (0.72) | IDO1TDO2KDM4EALDH1A1NPC1 | |
| SCHEMBL8595445 | 0.74 | IDO1 (0.82) | IDO1TDO2KMT2AGAA | |
| SCHEMBL396010 | 0.73 | IDO1 (0.58) | IDO1MIFGABRA1KDM4EALDH1A1 | |
| SCHEMBL11463722 | 0.73 | IDO1 (0.57) | IDO1MIFGABRA1KDM4EALDH1A1 | |
| SCHEMBL7805767 | 0.73 | IDO1 (0.71) | IDO1TDO2ALDH1A1NPC1RAB9A | |
| SCHEMBL7811800 | 0.73 | IDO1 (0.62) | IDO1TDO2KDM4EALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450281-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-6262095-B1 | TREATMENT OF ILLNESS ASSOCIATED WITH AN ALTERATION IN VENOUS FUNCTION AND/OR INFLAMMATORY EDEMA | LABORATOIRE INNOTHERA (FR) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450281-B1 | Compounds and methods for treating cancer | USP8, USP2, NEDD8 | IDO1 2561/4885TDO2 2554/4885MIF 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.